 SHANGHAI and SAN FRANCISCO, April 19, 2021 GLOBE NEWSWIRE -- Zai Lab Limited Zai Lab or the Company NASDAQ:ZLAB, HKEX: 9688, an innovative commercial stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 750,000,000 of American depositary shares ADSs, each representing one ordinary share of the Company. All ADSs will be offered by Zai Lab. Zai Lab expects to grant the underwriters a 30-day option to purchase additional ADSs. Investors have an option to receive ordinary shares of the Company Shares in lieu of ADSs in this offering only, and such option will not be available to purchasers of the additional ADSs. 